Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform
June 22 2022 - 8:00AM
Business Wire
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life
sciences company developing a new generation of bio-innovative
biologic medicines to improve patient access, safety, and
convenience, expanded its patent portfolio with the issuance of
U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera
exclusive rights pertaining to certain excipients in its SQore™
platform as viscosity-lowering agents to significantly optimize
filtration efficiency of protein solutions during the biologics
manufacturing process. The ‘857 patent reflects a significant
addition to Comera’s current intellectual property portfolio and
expands the potential commercial applications of SQore, broadening
patent protections beyond use in therapeutic antibody formulations
to include manufacturing process enhancement.
“We believe that the ‘857 patent will more broadly protect
SQore’s use in manufacturing process optimization and has the
potential of expanding SQore’s commercial value in biologic
manufacturing, as we work with our strategic partners to transform
the delivery of biologics to benefit patient care,” said Jeff
Hackman, Chief Executive Officer and Chairman of Comera. “We have
been significantly investing in the scientific development of our
SQore platform, and today’s patent issuance reflects our efforts to
strengthen our intellectual property position for SQore.”
Filtration of protein solutions is a key component of the
antibody manufacturing process and is utilized for sterilization,
removal of impurities, and concentration of the active ingredient
to allow for use as an injected medicine. The filtration steps can
be time consuming, costly, and inefficient, and an increase in
filtration rate could improve the economics of production. Comera
believes that its SQore technology, by lowering viscosity of high
concentration protein solutions, allows for high-throughput
filtration and a significantly more efficient manufacturing
process.
“The benefits of Comera’s viscosity-reducing SQore technology
goes well-beyond enabling subcutaneous drug formulations,” said
Alan Herman, Ph.D., a scientific advisor to Comera and former Chief
Scientific Officer of Coherus Biosciences. “High viscosity
encountered during the downstream processing phase of drug
manufacturing can significantly reduce efficiency, so technologies
like SQore that can lower viscosity offer the potential to greatly
optimize production throughput of antibody formulations.”
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life
Sciences is applying a deep knowledge of formulation science and
technology to transform essential biologic medicines from
intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences mission, as well as
the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking Statements
This press release contains includes “forward-looking
statements” within the meaning of the federal securities laws.
These forward-looking statements generally are identified by the
words “believe,” “project,” “expect,” “anticipate,” “estimate,”
“intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including, but not
limited to: risks that the recently completed business combination
disrupts the Company’s current plans and ability to retain its
employees; the Company’s ability to maintain the listing of its
securities on the Nasdaq Capital Market; the effect of the COVID-19
pandemic on the Company’s business; the price of the Company’s
securities may be volatile due to a variety of factors, including
changes in the competitive and highly regulated industries in which
the Company plans to operate, variations in performance across
competitors, changes in laws and regulations affecting the
Company’s business and changes in the capital structure; the
ability to implement business plans, forecasts, and other
expectations and identify and realize additional opportunities; the
risk of downturns and the possibility of rapid change in the highly
competitive industry in which the Company operates; the risk that
the Company and its current and future collaborators are unable to
successfully develop and commercialize the Company’s products or
services, or experience significant delays in doing so; the risk
that we will be unable to continue to attract and retain
third-party collaborators, including collaboration partners and
licensors; the risk that the Company may never achieve or sustain
profitability; the risk that the Company will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all; the risk that the Company
experiences difficulties in managing its growth and expanding
operations; the risk that third-party suppliers and manufacturers
are not able to fully and timely meet their obligations; the risk
that the Company is unable to secure or protect its intellectual
property; the risk that the Company is unable to secure regulatory
approval for its product candidates; general economic conditions;
and other risks and uncertainties indicated in the Current Report
on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors”
and in other filings that have been made or will be made with the
SEC. The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of Comera’s
Current Report on Form 8-K filed with the SEC on May 25, 2022 and
other documents filed by Comera from time to time with the SEC.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Comera assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Comera can
give no assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621006060/en/
Comera Investor John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press Karen Chase ICR Westwicke
Karen.Chase@westwicke.com
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Apr 2024 to May 2024
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From May 2023 to May 2024